Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAGED-PKD-EXT open-label extension of venglustat in rapidly progressive ADPKD
jRCT2031200348Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Small Molecules
01
Overview
Open-label trial of venglustat in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Sanofi. Primary endpoint: Percent change in total kidney volume (TKV). Started Feb 2021; status: completed.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCT2031200348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200348.